Caliway's CBL-514 Combination Therapy Cleared by U.S. FDA for Phase 2 Trial

Caliway's CBL-514 combination therapy has received FDA clearance to proceed into Phase 2 clinical trials and has also initiated patient enrollment for its pivotal Phase 3 trial SUPREME-01 in the United States.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.